Now I have enough data to write the article. Let me analyze the key findings:
Bearish options flow is dominating biotech ahead of a busy earnings week.
Cytokinetics shows the most striking setup. June 18 put open interest dwarfs calls by a wide margin. The $55 strike alone carries 5,955 contracts of put OI. The $40 puts hold 2,381 contracts. Calls at equivalent strikes sit near zero. Traders are paying for downside protection ahead of the company's upcoming results.
BioAge Labs is moving in the opposite direction. ORTEX flagged bullish options activity on the Nasdaq-listed biotech before its Q1 print. The $20 call strike holds 925 contracts of open interest. That's the largest single position across the chain. Implied premium is thin, suggesting traders expect a sharp move higher.
USA Rare Earth is attracting options traders too. The small-cap stock carries 16% of its float short. Weekly expiries are active all the way through June — unusual for its market cap size.
QXO stands out on macro screens. Days-to-cover hit 22. Its short score of 81 is among the highest in the US market. Options markets have not fully priced in a squeeze scenario yet. That gap is worth watching.
On SPY, daily expiry contracts are filling in every session through August. That density reflects elevated hedging demand. Macro risk — including Iran tensions and UK political turmoil — is driving traders to keep short-dated protection active.
This is not financial advice.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
